6 results about "C5a receptor" patented technology

Hydrochloride salt forms of synthetic C-terminal peptide analogs of C5a, which are response selective agonists of C5aR-bearing antigen presenting cells. Methods of inducing an immune response in a subject by administering such peptide analogs alone or in combination with other active agents are also disclosed.

The present invention relates to fused piperidinyl bicyclic compounds, meta-substituted piperidinyl compounds and related compounds that modulate the activity of the mammalian C5a receptor by direct binding to said C5a receptor for use in the treatment of disease, the diseases are in particular monosodium urate (MSU)-induced diseases, neutrophil-driven inflammatory nephropathy, skin neutrophil inflammatory diseases and immune complex diseases.

The invention relates to the technical field of biological medicines, in particular to application of a C5a receptor inhibitor PMX53 in preparation of a medicine for preventing and / or treating ejection fraction retention type heart failure. Experimental data provided by the invention show that the PMX53 effectively reverses the heart structural lesion related to the HFpEF. Histological analysis proves that the pathological hypertrophy of myocardial cells and the fibrosis process of myocardial interstitial substance are remarkably inhibited by PMX53 treatment. In addition, the overall hypertrophy degree of the heart is relieved through treatment. The discovery shows that PMX53 not only improves the heart function, but also intervenes and repairs myocardial structure damage caused by HFpEF on the tissue level.

There is a need to identify solid forms of Compound 1 that can improve important biological characteristics such as solubility, dissolution rate, and bioavailability without sacrificing stability and efficacy. The present disclosure addresses these needs and provides further related advantages.SOLUTION: Provided herein is an amorphous form of complement-component 5a receptor having the formula of Compound 1. Also provided herein are pharmaceutical compositions and methods of treatment using the amorphous form of Compound 1 described herein.SELECTED DRAWING: Figure 2